Pulmonary embolism is a disease that primarily affects young people, especially women, and the highest incidence occurs between the ages of 30-40. However, it can also appear in later years. Patients with pulmonary embolism were categorized based on level of function and level of risk, ranging from 1 (highest function) to 4 (lowest function).
For a decade, there was no progress in the treatment of pulmonary embolism, with existing treatments mainly aimed at relieving symptoms. However, the US Food and Drug Administration (FDA) recently approved a breakthrough drug called sotatracept, the first of its kind to treat the disease itself, not just the symptoms.
Sotatracept works with a unique mechanism by inhibiting the component “activin” to change the mechanism of the cells that drive the disease. This approval marks a significant improvement for patients with pulmonary hypertension, offering better survival rates, delaying disease progression and reducing the risk of worsening events or death by approximately 84%.
According to prof. To Mordechai Kramer, director of the pulmonary department at Blinson Hospital, pulmonary hypertension is a serious and life-threatening disease, and sotatracept offers new hope for patients who have not responded well to existing treatments. The Department of Health usually approves FDA-approved drugs after reviewing research findings submitted by the company.
In 2023, Rachel Franklin made headlines by winning two gold medals at the Guernsey Island…
As a journalist, I have rewritten the article to create a unique piece. Here it…
In a virtual news conference, Monterey County Health Director Elsa Jimenez expressed concern that Gov.…
Bridget and Ryan are eager to share their knowledge on money and economics with their…
In the first quarter of the year, Tencent surpassed analysts' expectations for both revenue and…
Marquette University has achieved an exceptional ranking in the top 5.5% of over 20,000 universities…